AMCP CEO Blog: AMCP has been working hard for several years to help members be ready when drugs are approved or off-label indications emerge. The first prong of our effort was to update the popular AMCP Format for Formulary Submissions.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released Part II of the Advance Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, outlining proposed payment changes and other requirements for plan sponsors participating in MA and the Part D program for the upcoming contract year.
On February 5, 2020, the Centers for Medicare & Medicaid Services (CMS) released the CY 2021 and 2022 Medicare Advantage and Medicare Prescription Drug Benefit Program Policy and Technical Rule, outlining proposed programmatic changes to the MA and Part D programs for two upcoming contract years. In a break from historic precedent, many of the program and policy changes that historically had been included in the Draft Call Letter were included in this proposed rule.
JMCP has added two prominent academic health care researchers to its editorial team, a move designed to keep pace with the growing influence of AMCP’s peer-reviewed, scientific journal.
AMCP CEO Blog: As a new decade dawns, AMCP is preparing for the twists and turns of an uncertain first year. With health care a top issue in this year’s presidential campaigns, drug pricing a favorite target, and biosimilar use poised to expand, seeing where this year will lead requires much more than “2020” vision.
AMCP has released Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new dossier types for biopharmaceutical manufacturers to share evidence on unapproved products and new indications that are under review by the U.S. Food and Drug Administration (FDA).
The Academy of Managed Care Pharmacy (AMCP) thanks the Office of Inspector General (OIG) for the opportunity to provide written comments regarding the new proposed rulemaking on “Medicare and State Healthcare Programs: Fraud and Abuse; Revisions to Safe Harbors Under the Anti-Kickback Statute, and Civil Monetary Penalty Rules Regarding Beneficiary Inducements” published in the Federal Register on October 17, 2019.
Increased simplicity, broader financial risk sharing, and an enhanced focus on patient care were among the recommendations developed by diverse stakeholders at a recent AMCP Partnership Forum focused on how to better manage the high costs of specialty medications.
In December 2016, AMCP applauded the passage of the 21st Century Cures Act as it included many provisions that will directly improve the health of Americans, from prompting new cures for cancer to combating opioid addiction.
Digital therapeutics: What are they, and where do they fit into pharmacy and medical benefits? Learn more in this blog post from AMCP CEO Susan A. Cantrell, RPh, CAE.